Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight – Oncology Nurse Advisor
Oncology Nurse Advisor |
Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight
Oncology Nurse Advisor Tisagenlecleucel, from Novartis Pharmaceuticals Corp, is the first chimeric antigen receptor (CAR) T cell immunotherapy to be granted approval. The agent consists of autologous T cells collected via leukapheresis that are genetically modified with a … |
